MedTrace Logo

Effect of Empagliflozin on Peritoneal and Kidney Function in End Stage Renal Disease

NCT05671991 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2026-05-22

No results posted yet for this study

Summary

The main purpose of the study is to determine if empagliflozin can reduce peritoneal glucose absorption in patients with end stage renal diease (ESRD) on peritoneal dialysis.

This is a randomized, placebo controlled, acute crossover study of empagliflozin in an anticipated 30 chronic PD patients, with an 8 week "pre post" open label extension in all 30 patients where they will receive empagliflozin daily.

Conditions

  • End Stage Renal Disease on Dialysis

Interventions

DRUG

Empagliflozin 25 mg vs Placebo

Acute Study- Empagliflozin 25 mg vs Placebo on D1 then alternate therapy on D7

DRUG

Empagliflozin 10 MG

Chronic Study- Empagliflozin 10 mg for 8 weeks

Sponsors & Collaborators

Principal Investigators

  • Jeffrey Testani, MD · Yale University

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-03-01
Primary Completion
2026-12-31
Completion
2026-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05671991 on ClinicalTrials.gov